Novavax, Inc. is nearing breakeven according to industry analysts, expecting profitability in 2024 after a final loss in 2023. With a projected 70% yearly growth rate, the company's path to profitability looks optimistic. However, negative equity on its balance sheet raises concerns.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing